Some Medicare patients will be able to access to GLP-1 medication for weight loss for the first time starting July 1, paying a $50 monthly copay through a new program designed to make the drugs more ...

For 35 years, Barbara Senich only owned black pants. “I thought somehow, that would make me look less big,” said Senich, 69, who has struggled with obesity for most of her life. At her heaviest, ...

Starting Wednesday, people on Medicare will be able to get weight loss drugs, including Wegovy and Zepbound, for $50 a month. But patients hoping for quick or permanent access to the drugs may be ...

Medicare is starting to cover weight-loss drugs for some seniors. Starting this Wednesday, the Centers for Medicare & Medicaid Services (CMS) will now offer eligible Medicare recipients access to ...

Medicare's upcoming weight-loss drug program could create major bottlenecks for doctors as millions of seniors seek access to popular GLP-1 treatments such as Wegovy and Zepbound. Clinicians are ...

John writes about the politics of health care, and he is the author of the twice-weekly D.C. Diagnosis newsletter. You can reach John on Signal at John_Wilkerson.07. WASHINGTON — Weight loss drugs ...

U.S. Air Force Secretary Troy Meink recently visited K2 Space in Torrance, California. K2 Space Wins First Program Of Record As PTS-G Bus Provider is published in Aerospace Daily & Defense Report, an ...

The South Florida Water Management District's Python Elimination Program rewards hunters for removing the invasive snakes. In May 2026, contracted hunters eliminated 315 python eggs from the ...

Bob covers the money in health care, focusing on health insurance and hospitals. His stories delve into Medicare Advantage, opaque prescription drug benefits, and how much executives actually make. He ...

Women battling breast cancer can benefit from a phone-based weight loss program, according to a new study. The Breast Cancer Weight Loss (BWEL) program helped women drop excess pounds, improve their ...

As Eli Lilly looks to hold its lead in the lucrative obesity market, the company’s next-gen prospect, the triple-G drug retatrutide, has met the primary endpoint for weight loss in another pivotal ...

“How do they do that?” is a reasonable response to certain things we see in nature. Pythons and snakes like them can eat prey as big as they are, sometimes even bigger, and digest their massive single ...